{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-25-000054","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.591972+00:00","generated_at":"2026-05-21T12:52:04.132034+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MacroGenics Q1 2025 net loss improves to $41M; cash runway into H2 2026","bullets":["Net loss of $41.0M ($0.65 loss per share) vs Q1 2024 loss of $52.2M ($0.84).","Revenue $13.2M, up from $9.1M, driven by collaborative agreements and contract manufacturing; no product sales after MARGENZA sale.","Cash, equivalents and marketable securities $154.1M as of Mar 31, 2025, down from $201.7M at Dec 31, 2024; runway projected into H2 2026.","First patient dosed in Phase 2 LINNET study of lorigerlimab in platinum-resistant ovarian and clear cell gynecologic cancers.","LORIKEET Phase 2 (lorigerlimab + docetaxel in mCRPC) clinical update expected in second half of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-25-000054","json":"https://secwatch.observer/filing/0001125345-25-000054.json","markdown":"https://secwatch.observer/filing/0001125345-25-000054.md","text":"https://secwatch.observer/filing/0001125345-25-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534525000054/0001125345-25-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534525000054/mgnx-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T12:52:04.132034+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}